Kornimate/medical-research-clean huggingface dataset:
development and pilot testing of a clinical informatics lung cancer screening intervention

Conditions: Lung Neoplasms

Summary: this study evaluates the feasibility of a clinical informatics system-based approach to lung cancer screening. patients of a large academic medical center who may qualify for lung cancer screening will be sent an electronic invitation to complete an online lung cancer screening decision aid.

the center for medicaid and medicare services (cms) recently approved the use of low-dose chest ct scans for lung cancer screening in patients who meet specific criteria. however, many individuals who meet these criteria do not realize they qualify for screening. this study will determine the feasibility of using a clinical informatics approach to systematically identify potential candidates for ldct screening, reach out to them via the patient portal, and use a web app to provide them with a personalized ldct screening decision aid and facilitate the ordering of screening tests.

Eligibility criteria:
inclusion criteria: * has an active patient portal account * scheduled to see a wake forest primary care provider within the next 4 weeks exclusion criteria: * never smokers * current or former history of lung cancer * receipt of chest ct scan within last 12 months * need for a language interpreter * presence of disease predicting short life-expectancy
an open-label extension study to evaluate the safety of the 13 mg bimatoprost ocular insert

Conditions: Primary Open-Angle Glaucoma; Ocular Hypertension

Summary: this study evaluated the long-term (9-months) safety of the bimatoprost ocular insert in participants with glaucoma or ocular hypertension who completed study fsv5-004. all the participants received bimatoprost ocular insert and wore it for approximately 3 months (12 weeks), then had that insert removed and a new insert placed for another 26 weeks (approximately 6 months).


Eligibility criteria:
inclusion criteria: 1. completed fsv5-004 study. 2. written informed consent prior to any study procedure. 3. willingness to comply with the visit schedule. key exclusion criteria: 1. participation in an investigational drug or device study other than fsv5-004 within the past 6 months or anticipated participation during the study period. 2. subjects who will require contact lens use during the study period. 3. any condition or situation (such as uncontrolled systemic disease) that, in the investigator's opinion, might confound the results of the study, may put the subject at significant risk or might interfere with the subject's ability to participate in the study.
an observational study of continued bevacizumab plus chemotherapy until first progression in participants with metastatic colorectal cancer (crc)

Conditions: Colorectal Cancer

Summary: this prospective, multicenter, observational study will investigate the effectiveness and safety of bevacizumab in routine clinical practice in participants with metastatic crc. participants are to have initiated first-line treatment with fluoropyrimidine-based doublet chemotherapy plus bevacizumab according to the bevacizumab summary of product characteristics (smpc).


Eligibility criteria:
inclusion criteria: * participants with histologically confirmed crc with metastatic lesion * participants having initiated first-line treatment with fluoropyrimidine-based doublet chemotherapy plus bevacizumab according to bevacizumab smpc * participants who previously received a minimum 9 cycles of 5-fu-based or a minimum 6 cycles of capecitabine-based induction doublet chemotherapy (i.e. 5-fu or capecitabine + oxaliplatin or irinotecan) plus bevacizumab * disease evaluation showed stable disease, partial response, or complete response according to recist within one month exclusion criteria: * contraindication to receive bevacizumab according to the bevacizumab smpc * participants who received more than 10 cycles of 5-fu-based or more than 7 cycles of capecitabine-based induction doublet chemotherapy plus bevacizumab * pregnant or lactating women
a real-world registry investigating treprostinil sodium in pulmonary hypertension (re-triumph)

Conditions: Pulmonary Hypertension; Medication Therapy Management

Summary: a real-world registry investigate treprostinil sodium used in patients with pulmonary hypertension (re-triumph).

this study is a multicenter, prospective, single-arm, observational, real-world study conducted in china. patients who are at least 18 years of age, have been diagnosed with pulmonary hypertension (ph), agree to participate and meet the eligibility requirement will be enrolled in 20 pulmonary vascular centers across the country for the medically reasonable use of intravenous (or subcutaneous) treprostinil injections. in the event that eligible patients are enrolled in the study, all aspects will be carried out in an observational manner, and no additional methods or procedures will be necessary. the patient and the physician will jointly determine the clinical management of the patient, including the length of treatment. patients will be followed up for an observation period of at least 1 year. as part of standard clinical practice, patient data will be collected at the first appointment and every three to six months thereafter. after one year of follow-up, data collection will cease.the main purpose is to evaluate the efficacy and adverse reactions of subcutaneous (intravenous) prostacyclin in the treatment of pulmonary hypertension under current clinical practice. the secondary objectives is to understand the drug treatment plan of treprostinil in clinical practice of patients with pulmonary arterial hypertension in china and to understand the efficacy and adverse reactions of treprostinil in the treatment of patients with different types of pulmonary hypertension.

Eligibility criteria:
inclusion criteria: * patients with pulmonary hypertension who consent to receiving treprostinil injection; * patients who must be over the age of 18; * the informed consent form must be signed. exclusion criteria: * patients who have received treprostinil injection for less than two weeks; * patients who have used treprostinil within the past three months; * any situation that the investigator believes could affect the interpretation of the study results or pose a risk to patients using treprostinil.

Keywords: pulmonary hypertension trepostinil sodium
connect™ cll: the chronic lymphocytic leukemia disease registry

Conditions: Chronic Lymphocytic Leukemia

Summary: the purpose of the connect™ chronic lymphocytic leukemia (cll) disease registry is to explore the history and real world management of patients diagnosed with cll, provide insight into the management of cll, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employed in both the community and academic settings.


Eligibility criteria:
inclusion criteria: * clinical diagnosis with cll * clinical decision made to initiate first-line therapy, second-line therapy or subsequent line of therapy prior to enrollment into the connecttm cll registry, but within 2 months of enrollment * age≥18 years * willing and able to provide signed informed consent * willing and able to complete patient assessment questionnaires either alone or with minimal assistance from caregivers and/or trained site personnel exclusion criteria: * participation in a clinical study in which study treatment is blinded * patient condition is considered terminal (i.e.\<6 months to live)

Keywords: chronic lymphocytic leukemia cll disease registry connect™
time of intravenous acetaminophen administration

Conditions: Osteoarthritis

Summary: the purpose of the study is to examine the effects of timing of administration of intravenous (iv) acetaminophen and how timing relates to analgesic efficacy as measured by postoperative pain scores. a maximum of 138 patients meeting inclusion criteria who present for a scheduled total hip replacement under general anesthesia will be randomized into one of two arms: 1) the pre-closure group will receive the first dose administered upon onset of skin closure, 2) the preemptive group will receive the first dose administered within 60 minutes prior to incision. both groups will receive subsequent doses every 6 hours x 24 hours.

the purpose of the study is to examine the effects of timing of administration of intravenous (iv) acetaminophen and how timing relates to analgesic efficacy as measured by postoperative pain scores. a maximum of 138 patients meeting inclusion criteria who present for a scheduled total hip replacement under general anesthesia will be randomized into one of two arms: 1) the closure group will receive the first dose of one gram of intravenous acetaminophen administered upon onset of skin closure, 2) the preemptive group will receive the first dose of one gram of intravenous acetaminophen administered within 60 minutes prior to incision. both groups will receive subsequent doses of one gram of intravenous acetaminophen every 6 hours x 24 hours. the maximum dose in a 24 hour period will not exceed 4 grams according to fda recommendations.

Eligibility criteria:
inclusion criteria: * patients 30-75 years of age weighing ≥55 kg scheduled for elective total hip arthroplasty performed under general anesthesia will be included. as determined by the anesthesia team assigned to the case, eligible patients will also be assigned asa physical status of i, ii, or iii and deemed capable of reporting their perceived pain using numeric pain scales and capable of operating a patient controlled anesthesia (pca) device. exclusion criteria: * exclusion criteria include known allergy, hypersensitivity, or contraindication to acetaminophen, history of alcohol or drug abuse, prisoners, emergency thas, patients with chronic malnutrition or a body mass index (bmi) \ 2.0 mg/dl).

Keywords: acetaminophen timing arthroplasty
left atrial volume and function evaluation in patients with obstructive sleep apnea

Conditions: Sleep Apnea Syndromes

Summary: the purpose of this study is to determine whether patients with obstructive sleep apnea have any changes in left atrial morphology and function evaluated by echocardiography three dimensional

several studies have been suggesting that obstructive sleep apnea contributes to deterioration of left ventricular diastolic function . it may lead to atrial myocardium stretching and enlargement which may be associated to increased risk of cardiovascular events. we hypothesized that morphological and functional la changes might be found using three dimensional echo, and that such alterations are related to obstructive sleep apnea presence.

Eligibility criteria:
inclusion criteria: * age from 30 to 70 * apnea-hypopnea index \> 5 by polysomnography exclusion criteria: * any cardiac disease * poor imaging quality by mean of echocardiography * non-sinusal rhythm

Keywords: sleep apnea syndromes diastolic disfunction left atrium
a continuation study of tak-279 in adults with ulcerative colitis (uc) and crohn's disease (cd)

Conditions: Crohn's Disease; Ulcerative Colitis

Summary: crohn's disease and ulcerative colitis are two types of inflammatory bowel disease (ibd), which is a serious, long-term condition in the gut (intestine) that can cause pain and swelling (inflammation) in the bowel. tak-279 is a medicine which helps to block inflammation. this study is an extension of the parent studies, tak-279-cd-2001 (nct06233461) and tak-279-uc-2001 (nct06254950). this means that participants who responded to treatment with tak-279 in either of the parent studies may be able to continue to benefit from the treatment in this study. the main aim of this study is to find out how safe tak-279 is for long term use and to check if it reduces bowel inflammation and symptoms when used for a longer period of time in adults with moderately to severely active uc or cd. the participants will be treated with tak-279 for up to 2 years (108 weeks). during the study, participants will visit their study clinic 11 times.


Eligibility criteria:
inclusion criteria: 1. the participant is willing and able to understand and fully comply with trial procedures and requirements (including digital tools and applications), in the opinion of the investigator. the participant has provided informed consent (that is, in writing, documented via a signed and dated informed consent form \[icf\]) and any required privacy authorization prior to the initiation of any trial procedures. disease-specific inclusion criteria: 2. completion of week 52 in the parent phase 2 cd and uc trials with valid electronic (e) diary data for week 52 (tak-279-cd-2001 and tak-279-uc-2001). 3. clinical or symptomatic responder at parent trial week 52 as defined below: 1. tak-279-cd-2001: clinical response in pro2 at parent trial week 52, assessed as \>=30% decrease in average daily very soft or liquid stools and/ or \>=30% decrease in average ap from parent trial baseline. 2. tak-279-uc-2001: symptomatic response at parent trial week 52, assessed as a reduction in partial modified mayo score (pmms) of \>=1 points and \>=30% from parent trial baseline; and a decrease from parent trial baseline in the rectal bleeding sub-score of \>=1 point or an absolute rectal bleeding sub-score of \<=1 point. other general inclusion criteria: 4. participants must meet the contraception recommendations. exclusion criteria: 1. participant considered by the investigator to be unsuitable for the ole trial due to their trial compliance and medication adherence concerns. 2. participants with malignancy or dysplasia per endoscopy any time during the parent trial or at the beginning of the ole. exclusion criteria related to laboratory investigations: 3. participants meeting the exclusion criteria related to laboratory investigations as defined in the protocol. exclusion criteria related to other prohibited concomitant medication: 4. participants taking oral corticosteroids for cd or uc during parent trial at or after week 48.

Keywords: drug therapy
use lay language. ha score to identify myeloma patients who could benefit from hdaci treatment

Conditions: Patients With Recurrent or Refractory Multiple Myeloma

Summary: panobinostat is a potent oral histone deacetylase inhibitor that alters gene expression through epigenetic mechanisms and inhibits protein degradation. it was recently approved by the us food and drug administration for use in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma (mm) who have received ≥ 2 prior regimens, including bortezomib and an immunomodulatory drug. a gep-based histone acetylation score allowing identification of mm patients with a poor prognosis and who could benefit from hdaci treatment was recently reported(moreaux et al. bjc. 2013). our hypothesis is that the histone acetylation score could be promising to identify mm patients who could benefit from treatment with hdaci and the development of personalized treatment.


Eligibility criteria:
inclusion criteria: * relapsed/refractory multiple myeloma * aged 18 years or more with no upper age limit * have signed an informed consent exclusion criteria: na

Keywords: multiple myeloma hdac inhibitor biomarker
tumor landscape pathological diagnosis by large tissue sections

Conditions: Pathology

Summary: the aim of this study is to establish large tissue sections for 10 kinds of tumors. in order to observe the tumor landscape on microscope. the tumors including esophageal carcinoma,gastric carcinoma,hepatocellular carcinoma etc.200 cases of each tumor will be compared by traditional sample method and landscape sample method to testify the clinical value and significance of tumor landscape pathological diagnosis .


Eligibility criteria:
inclusion criteria: 1. older than 15-year-old 2. did not receive preoperative preoperative chemotherapy or radiotherapy exclusion criteria: patients undergoing preoperative chemotherapy or radiotherapy

Keywords: tumor ,landscape ,pathological diagnosis
(men who have sex with men) msm community intervention trial

Conditions: HIV; Syphilis; Herpesvirus 2, Human

Summary: the purpose of this study is to evaluate the effectiveness of the community based comprehensive hiv/stis intervention among msms in china.

national sentinel surveillance data show that hiv infections are increasing fast among men who have sex with men(msm) in china. in some cities hiv prevalence among msm is higher than 10%.it is urgent for china to explore innovative intervention to reduce hiv/aids transmission among this population. the purposes of this study are: 1. to evaluate the effectiveness of comprehensive interventions to decrease the hiv/stis incidence among msm population in china. the comprehensive intervention components include male circumcision, pol intervention, hiv testing and counseling and condom promotion. 2. to determine the acceptability of male circumcision among msm population in china.

Eligibility criteria:
inclusion criteria: * 18 years or above * male have oral sex or anal sex within 6 months with a man * accept questionnaire survey and blood test * can participate in three surveys in one year * hiv negative * no mental disease and can understand informed consent exclusion criteria: -

Keywords: msm intervention popular opinion leader male circumcision hiv syphilis hsv-2
collection of blood and/or bone marrow for investigation and characterization of normal and abnormal cell growth

Conditions: Leukemia

Summary: the collection of blood and/or bone marrow from patients with blood disorders, blood cell malignancies and associated conditions will serve as a convenient and comprehensive source of tissue to give us further information about the differences between normal blood cells and blood cells of affected individuals. this will be an invaluable asset for understanding the biology of blood disorders. the collected samples will be used by investigators for studies including immunology, molecular biology and genetics to name a few.


Eligibility criteria:
inclusion criteria: * selected patients over the age of 18 with hematologic malignancies or other blood disorders (leukemia, myeloproliferative disorders, lymphoma, other malignancies involving the bone marrow or patients with unexplained alterations in their complete blood count). patients who are scheduled to undergo a bone marrow aspirate and/or phlebotomy for other clinical indications will be asked to participate. they will be asked to donate an additional small aliquot of bone marrow and/or blood during the course of their already scheduled bone marrow aspiration or phlebotomy. exclusion criteria: * patients with pre-existing medical conditions that might be exacerbated by the procedure of obtaining bone marrow or blood * patients who are allergic to lidocaine, which is used as a local anesthetic, and who cannot receive a suitable substitute anesthetic. * patients who have a bleeding diathesis which might pose a problem with marrow aspiration. * patients unable to give informed consent. * pregnant patients

Keywords: blood/bone marrow collection, hematologic diseases, leukemia
the effect of acupressure on dyspnea and anxiety levels

Conditions: COPD (Chronic Obstructive Pulmonary Disease)

Summary: the aim of this study is to determine the effect of acupressure applied to individuals with copd on dyspnea and anxiety. it is important for the transfer of nonpharmacological methods to clinical applications.

the pathophysiological changes that occur in the airways and alveoli in chronic obstructive pulmonary disease can cause many symptoms such as dyspnea, cough and sputum, which restrict the daily lives of individuals. dyspnea and anxiety are at the top of the list among these symptoms, which affect individuals in many ways and limit them in many areas. while physiological, psychological and sociological factors cause dyspnea, the anxiety that develops in patients along with dyspnea also accompanies the symptoms. these symptoms seen in individuals with copd not only negatively affect the quality of life of individuals, but also bring about psychological, cognitive, economic and social problems. therefore, reducing anxiety and dyspnea in patients with copd is of great importance in controlling the symptoms. recently, acupressure has been frequently preferred among non-pharmacological methods in symptom control. as a result of studies conducted with different patient groups in the literature, it has been stated that acupressure reduces dyspnea and anxiety levels. in this study, five tools will be used: patient identification form, modified borg dyspnea scale (mbs), medical research council (mrc) dyspnea scale, beck anxiety scale (baö) and patient follow-up schedule. individuals will be applied acupressure once a day for two minutes at li4, ht7, lu1, st36 points, for a total of 20 sessions. it is of great importance for nurses to follow current care methods, include them in nursing care and improve themselves in this regard. no current study has been found in the literature investigating the effect of acupressure applied to individuals with copd on dyspnea and anxiety. the purpose of this study is to determine the effect of acupressure applied to individuals with copd on dyspnea and anxiety.

Eligibility criteria:
inclusion criteria: patients who are literate, have moderate and severe stage copd according to gold criteria, score 8 and above on the beck anxiety inventory, patients who volunteer to participate in the study will be included in the study. exclusion criteria: * patients using psychiatric medication (anxiolytic, antidepressant), those with serious pulmonary, cardiological or malignant diseases, those with vision and hearing problems, those with communication problems, those with nerve, soft tissue and vascular diseases in the areas where acupressure will be applied, those with infections and surgical operations in the areas where acupressure will be applied, patients in the exacerbation period were not included in the study.
improvement of depression with use of atp

Conditions: Depression

Summary: this clinical study is a randomized, double-blind, placebo-controlled trial with an intervention period of 4 weeks. participants will be patients with moderate to severe depression who meet the inclusion criteria during the screening period. after recruitment written informed consent form will be signed and the baseline evaluation will be done then the treatment period follows. the subjects will be randomly assigned to a control group (escitalopram plus normal saline(na)) and an atp group (escitalopram plus adenosine disodium triphosphate(atp)) in a 1:1 ratio for treatment, with a total number of 120 recruited patients. assessment will be carried out as an analysis of changes in hamilton depression scale（hamd-24）, cognitive function test, brain functional network, inflammatory markers, and other indicators in the first, second, and fourth week of intervention which will evaluate the effectiveness of atp in improving moderate to severe depression preliminarily.


Eligibility criteria:
inclusion criteria: * meet the diagnostic and statistical manual of mental disorders-5 diagnostic criteria for moderate to severe depression. * hamd-24 scores ≥ 20. * 18-65 female or male. * participants who have not used any psychotropic medications within one month prior to study and never had a treatment with escitalopram. * individuals without contraindications to selective serotonin reuptake inhibitor. * individuals without contraindications to atp. * written informed consent. exclusion criteria: * participants with various major mental disorders other than depression (bipolar disorder, any psychotic disorder, personality disorders, alcohol use disorder, substance use disorder, and disorders due to medical or organic cause) assessed using chinese version of the mini international neuropsychiatric interview (mini). * individuals with neurological disorders such as dementia. * individuals with a high risk of suicide. * pregnant and lactating women. * contraindications to mri. * physician evaluation was not suitable for participants in this study.